Misfolded Proteins in the Skin of People With Parkinson's Disease and Other Parkinsonism

Description

The purpose of this study is to determine whether identification of misfolded proteins in the skin will help to determine what sort of parkinsonism someone has. We seek to demonstrate whether someone has a synucleinopathy such as Parkinson's disease (PD), multiple system atrophy (MSA), or dementia with Lewy bodies(DLB), as opposed to a tauopathy such as progressive supranuclear palsy (PSP) or corticobasal degeneration (CBD) or no parkinsonism at all (control).

Conditions

Parkinson Disease, Parkinsonism, Dementia With Lewy Bodies, Multiple System Atrophy, Progressive Supranuclear Palsy, Corticobasal Degeneration

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of this study is to determine whether identification of misfolded proteins in the skin will help to determine what sort of parkinsonism someone has. We seek to demonstrate whether someone has a synucleinopathy such as Parkinson's disease (PD), multiple system atrophy (MSA), or dementia with Lewy bodies(DLB), as opposed to a tauopathy such as progressive supranuclear palsy (PSP) or corticobasal degeneration (CBD) or no parkinsonism at all (control).

Assessing Skin Biomarkers for Preclinical Diagnosis of PD and Non-PD Parkinsonism

Misfolded Proteins in the Skin of People With Parkinson's Disease and Other Parkinsonism

Condition
Parkinson Disease
Intervention / Treatment

-

Contacts and Locations

Cleveland

University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States, 44106

South Euclid

University Hospitals Suburban Health Center, South Euclid, Ohio, United States, 44121

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age 21 years old and age \<90 years of age at the time of the baseline visit 1
  • * Age of diagnosis at least 40 years old for PD, DLB, and PSP and at least 30 years old for MSA
  • * A confirmed diagnosis of PD, PSP, CBD, MSA, DLB, or healthy control
  • * Montreal Cognitive Assessment (MoCA) \> 10 at the outset of the study
  • * Age 90 or above
  • * Allergy to local anesthetic
  • * History of deep brain stimulation (DBS) or other brain surgery prior to Visit 1
  • * For PD or DLB diagnoses, any other neurodegenerative or central nervous system process that would interfere with examination
  • * For PD or DLB, history of negative DATscan
  • * Use of investigational drugs or devices within 60 days prior to baseline visit (except for dietary supplements)
  • * In control subjects, family history of a neurodegenerative disease in a first degree or second degree blood relative
  • * History of schizophrenia
  • * History of antipsychotic medication use or exposure in controls or history of antipsychotic medication leading to parkinsonism (drug induced parkinsonism) in the parkinsonism group
  • * Blood clotting disorder
  • * On multiple (more than one) antiplatelet and/or anticoagulant blood thinner medications in combination (except for aspirin if it can be safely held for 1 week)
  • * Any other medical, psychiatric, or cognitive illness that in the investigator's opinion would interfere with cooperation or ability to undergo the study procedures.

Ages Eligible for Study

21 Years to 89 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

University Hospitals Cleveland Medical Center,

Steven Gunzler, MD, PRINCIPAL_INVESTIGATOR, University Hospitals Cleveland Medical Center and Case Western Reserve University

Chen Shu, PhD, PRINCIPAL_INVESTIGATOR, University of Alabama at Birmingham

Zerui Wang, MD, PhD, PRINCIPAL_INVESTIGATOR, Case Western Reserve University

Qingzhong Kong, PhD, PRINCIPAL_INVESTIGATOR, Case Western Reserve University

Study Record Dates

2025-05-31